GMP manufacturing
Scale-up, analytical methods, release strategy, and quality controls.
03 / Development
A focused lead program with a modular follow-on pipeline.
The platform is being advanced through a lead gynecologic oncology program and two additional programs intended to demonstrate repeatability across targets and indications.
Program
Focus
Current development objective
AT-201Lead program
Gynecologic cancers; follow-on potential in TNBC and NSCLC
GMP manufacturing and planned Phase 1b/2 clinical development
AT-202Follow-on program
Anti-PD-L1 nanoparticle program
CMC transition and preparation for clinical development
AT-203Follow-on program
T-cell lymphoma / anti-CD3 concept
Program definition and clinical-readiness planning
Partnering & financing
Advancing the platform with partners and investors.
Mayo Clinic plans to advance the Nanovia platform with partners and investors and is actively exploring Series A financing to support GMP manufacturing, clinical development, and the advancement of priority programs.
AT-201 clinical study
Initiation and execution of the planned Phase 1b/2 program.
Pipeline preparation
Advance two follow-on products toward clinical readiness.
Program infrastructure
Clinical, regulatory, and operational capabilities needed for execution.